



Id	Research Ethics Committee Reference Number	Name of Trial	Target number of patients available	Target number of patients	Date Agreed to recruit target number of patients available	Date Agreed to recruit target number of patients	Trial Status
72437	08/H0605/65	CC-5013-mm-020/ifm 07-01 (Celgene FIRST) MM020	Available	6	Available	07/12/2010	Closed - In Follow Up
72438	09/H1307/90	A Phase 2, Multicentre, Randomised, Open-Label, Parallel Group Study to Evaluate	Available	10	Available	30/06/2012	Closed - In Follow Up
72439	10/NIR02/64	GOLIATH - Greenlight Laser	Available	12	Available	11/09/2012	Closed - Follow Up Complete
72440	11/YH/0349	LOFRIC	Available	3	Available	07/04/2014	Closed - Follow Up Complete
72441	13/NW/0363	OSLER 2	Available	1	Available	01/11/2015	Closed - In Follow Up
72442	13/NW/0462	ACACIA - ADP04	Available	26	Available	30/10/2014	Closed - Follow Up Complete
72443	13/SC/0364	TPO5	Available	10	Available	31/07/2015	Closed - Follow Up Complete
72444	13/NW/0193	TRUS NX1207	Available	5	Available	31/12/2014	Closed - Follow Up Complete
72445	13/YH/0282	ACTMOVE: ML28641- Subcutaneous tocilizumab in Rheumatoid Arthritis.	Available	5	Available	29/08/2016	Closed - In Follow Up
72446	14/YH/0080	PAD: Feasibility study to evaluate non-invasive cycloidal vibration therapy for the s	Available	30	Available	31/01/2015	Closed - In Follow Up
72447	14/EE/0059	AQESYS - Evaluation of the AqueSys XEN Implant in Moderate Primary Open Angle	Available	10	Available	08/12/2014	Closed - In Follow Up
72448	14/YH/0023	AQUACEL - A multi centre study to assess the safety and performance of AQUACEL	Available	2	Available	30/09/2014	Closed - Follow Up Complete
72449	12/LO/1270	PRONOX 1 - A clinical pilot study of an oxides of nitrogen (NOx) – generating gel dr	Available	8	Available	28/08/2015	Closed - Follow Up Complete
72450	14/NW/1258	ARAMIS - Phase 3 efficacy & safety study of ODM201 in high risk nonmet CRPC	Available	4	Available	31/05/2020	Open
72451	14/EM/1307	ESTHER	Available	12	Available	23/02/2023	Open
72452	14/LO/1539	CANDLE - Nocturna 400 treatment for Diabetic Retinopathy. Pilot Study to demon	Available	10	Available	31/10/2015	Open
72453	15/WA/0241	DEPICT2 - A Multicentre, Randomized, Double-Blind, Placebo-controlled, Parallel G	Available	7	Available	20/12/2016	Open

Target met within the agreed time	Comments	Errors		
N	Very few eligible patients			
N	Eligible patients either declined or were sent for transplant so unable to recruit. 14 patients were screened			
N	Study closed early due to poor recruitment			
Y	Closed early nationwide due to poor recruitment. Recruitment target adjusted according to the NIHR/Sponsor contract			
Y	This study is a follow on from another. Originally expected 2 recruits but due to hold ups with the SIV the 1st patient dropped out so it wouldn't have been possible to recruit more than 1 other expected patient therefore expected recruitment target changed to 1.			
N	Original expected was 5 per month this was dropped to 2-3 per month as only breast patients able to be approached			
N/A				
N	Recruitment period extended due to poor recruitment nationwide. closed early due to no proven benefit			
N/A				
N				
N				
Y	Target number of patients in the SSI was the National target. 2 adult patients only were selected at this site.			
N/A				
N/A	letter from sponsor saying open to recruitment on 11/06/2015			
N/A	Rare patient group			
N	no patients meeting eligibility criteria were identified.			
N/A				